AEON Biopharma reports FY 2023 results; aligns with FDA on Phase 3 migraine design

AEON Biopharma, Inc.

End-of-Phase 2 meeting with FDA achieved alignment on pivotal Phase 3 trial design for episodic and chronic migraine.
Phase 2 chronic migraine study completed enrollment (492 patients); interim analysis data expected Q2 2024.
Announced $15M private placement of senior secured convertible notes with Daewoong; first $5M closed, second $10M due April 2024.
Cash runway projected through June 2024 only; company to fund late-stage clinical development.
No financial results provided in press release beyond qualitative business update.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AEON Biopharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.